��ɫ��

��ɫ��

Donate To Research Join The AAN

Events

Resources For

Abstract Details

Title Impact of Fremanezumab on the Number of Days with Use of Acute Headache Medications in Chronic Migraine

Topic Headache

Presentation(s) P4 - (-)

Poster/Presentation
Number 101

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Ernesto Aycardi, MD (Kyowa Kirin) PRESENTER	Dr. Aycardi has received personal compensation for serving as an employee of XENON. Dr. Aycardi has received stock or an ownership interest from XENON.
	No disclosure on file
Tricia Blankenbiller	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Egilius L. Spierings, MD, PhD (MEDVADIS RESEARCH)	Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Manistee. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lundbeck. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. Dr. Spierings has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Abbvie.
Marcelo E. Bigal, MD, PhD (Purdue)	No disclosure on file